PBR06
Phase 3Small molecule
PBR06 is one of 39 small molecule programs targeting Movement Disorder. It is currently in Phase 3.
2
Indications
10
Total Trials
1
Active Trials
38
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
138 competitors in Multiple Sclerosis
#DrugCompanyPhaseTrials
1Rinvoq
AbbViePhase 3
Questran
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Vumerity
BiogenPhase 3
Clemastine Fumarate
NovartisPhase 3
Mayzent
NovartisPhase 3
Activated Charcoal
SanofiPhase 3
Antihistamine
Arrowhead PharmaceuticalsPhase 3
Frexalimab
SanofiPhase 3
Tolebrutinib
SanofiPhase 3
PBR06
UUniversity Hospital, Bordeaux
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Multiple Sclerosis4 trials
PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases
Recruiting·—·Phase 1/2·NCT02649985·250 enrolled
Effect of Alemtuzumab on Microglial Activation Positron Emission Tomography (PET) in Multiple Sclerosis
Withdrawn·—·Phase 1/2·NCT03983252
9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis
Completed·—·Phase 3·NCT04510220·10 enrolled
ALS1 trial
Imaging1 trial
Establishing 18F-PBR06 PET Imaging as a Viable Pharmacodynamic Endpoint in MSA
Completed·—·Phase 1/2·NCT03033680·17 enrolled
Inflammation1 trial
Movement Disorder1 trial
Longitudinal Tracking of Patients Diagnosed With Neurodegenerative Movement Disorders
Unknown status·—··NCT05486806·50 enrolled
2 more indications
Stroke1 trial
Unspecified1 trial
Effect of Verdiperstat on Microglial Activation in Well-characterized MSA Patients
Completed·—·Phase 1·NCT04616456·19 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PBR06. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity Hospital, Bordeaux